Amzeeq (minocycline; Foamix) topical foam 4% will soon be available (January 13, 2020) by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.
Amzeeq utilizes Foamix’s proprietary Molecule Stabilizing Technology (MST) platform to deliver minocycline, a tetracycline-class drug, in a foam formulation; it is the first FDA-approved topical minocycline treatment for moderate to severe acne vulgaris.
Each gram of Amzeeq topical foam contains 40mg of minocycline equivalent to 43mg of minocycline HCl and is supplied in 30g aerosol cans. The propellant in the product is flammable, therefore patients should avoid fire, flame, and smoking during and immediately following application.
Amzeeq should be applied to acne-affected areas once daily at approximately the same time each day at least 1 hour before bedtime.
The list price for a 30g canister is $485. For commercially insured patients, Foamix provides a copay card for use with a valid prescription. In addition, an electronic benefit verification tool is available at Amzeeq.com to help providers and patients better understand costs and available savings options.
For more information visit amzeeqhcp.com.
This article originally appeared on MPR